Search by Drug Name or NDC
NDC 00310-4600-12 BEVESPI AEROSPHERE 4.8; 9 ug/1; ug/1 Details
BEVESPI AEROSPHERE 4.8; 9 ug/1; ug/1
BEVESPI AEROSPHERE is a RESPIRATORY (INHALATION) AEROSOL, METERED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AstraZeneca Pharmaceuticals LP. The primary component is FORMOTEROL FUMARATE; GLYCOPYRROLATE.
MedlinePlus Drug Summary
Formoterol oral inhalation is used to control wheezing, shortness of breath, and chest tightness caused by chronic obstructive pulmonary disease (COPD; a group of lung diseases that includes chronic bronchitis and emphysema). Formoterol is in a class of medications called long-acting beta agonists (LABAs). It works by relaxing and opening air passages in the lungs, making it easier to breathe.
Related Packages: 00310-4600-12Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Formoterol Oral Inhalation
Glycopyrrolate oral inhalation is used as a long term treatment to control wheezing, shortness of breath, coughing, and chest tightness in patients with chronic obstructive pulmonary disease (COPD; a group of diseases that affect the lungs and airways, that includes chronic bronchitis and emphysema). Glycopyrrolate is in a class of medications called anticholinergics. It works by relaxing the muscles around the airways in your lungs, making it easier to breathe.
Related Packages: 00310-4600-12Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Glycopyrrolate Oral Inhalation
Product Information
| NDC | 00310-4600 |
|---|---|
| Product ID | 0310-4600_4de58592-1f9d-4bf9-bf77-2356095c1745 |
| Associated GPIs | 44209902543220 |
| GCN Sequence Number | 075984 |
| GCN Sequence Number Description | glycopyrrolate/formoterol fum HFA AER AD 9-4.8 MCG INHALATION |
| HIC3 | B62 |
| HIC3 Description | BETA-ADRENERGIC AND ANTICHOLINERGIC COMBO, INHALED |
| GCN | 41199 |
| HICL Sequence Number | 043352 |
| HICL Sequence Number Description | GLYCOPYRROLATE/FORMOTEROL FUMARATE |
| Brand/Generic | Brand |
| Proprietary Name | BEVESPI AEROSPHERE |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Glycopyrrolate and formoterol fumarate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | AEROSOL, METERED |
| Route | RESPIRATORY (INHALATION) |
| Active Ingredient Strength | 4.8; 9 |
| Active Ingredient Units | ug/1; ug/1 |
| Substance Name | FORMOTEROL FUMARATE; GLYCOPYRROLATE |
| Labeler Name | AstraZeneca Pharmaceuticals LP |
| Pharmaceutical Class | Adrenergic beta2-Agonists [MoA], Anticholinergic [EPC], Cholinergic Antagonists [MoA], beta2-Adrenergic Agonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA208294 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00310-4600-12 (00310460012)
| NDC Package Code | 0310-4600-12 |
|---|---|
| Billing NDC | 00310460012 |
| Package | 120 AEROSOL, METERED in 1 INHALER (0310-4600-12) |
| Marketing Start Date | 2016-10-03 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 38.7304 |
| Pricing Unit | GM |
| Effective Date | 2024-01-01 |
| NDC Description | BEVESPI AEROSPHERE INHALER |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |